CPX-351 was approved by the Food and Drug Administration (FDA) in 2017 as an induction chemotherapy regimen for patients with AML-MRC or t-AML as defined by 2016 World Health Organization (WHO) classification. A large randomized phase 3 study that led to approval of CPX-351 included only ...
Lin3, Kobby Asubonteng4, Stefan Faderl5, Jeffrey E. Lancet6 and Thomas Prebet7 Abstract CPX-351 (Europe: Vyxeos® liposomal; United States: Vyxeos®) is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. ...
NR & D Protocol Converter, CAT2-BT, RS-422/485, RS-232, Omron CJ1W-V600C12 CJ1WV600C12 ID Sensor Unit Habor Precise Heat Pipe Heat Exchanger, Model HPC-35A Ingersoll Rand N+1 Module, 99340465, 99340473, S/W 89994R02 Load Controls, Inc. Control Load Compensator, XCR-1830V R1 R2 ...
Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients 60-75 Years of Age with Secondary Acute Myeloid LeukemiaA randomized trial comparing idarubicin plus cytarabine (IDA/Ara-C) with doxorubicin plus cytarabine (ADM/Ara-C) in induction ...